Education
About Us
Working with TipRanks
Follow Us
Myomo Inc (MYO)
XASE:MYO
Top Page
Myomo
(NYSE MKT:MYO)
Select Model
Select Model
Rating:51Neutral
Price Target:
$1.00
▲(8.70% Upside)
The overall stock score reflects a balance between strong revenue growth and strategic initiatives against the backdrop of profitability and cash flow challenges. The recent loan provides financial support, but the company must address operational inefficiencies to improve its financial health.
Positive Factors
Revenue Growth
Significant growth in the O&P channel indicates strong demand and successful market penetration, supporting long-term revenue expansion.
International Market Success
Strong international performance, especially in Germany, highlights Myomo's ability to expand globally, diversifying revenue streams and reducing reliance on domestic markets.
Financial Flexibility
The new loan enhances financial flexibility, allowing Myomo to invest in growth initiatives and manage operational needs, supporting long-term strategic goals.
Negative Factors
Decreased Gross Margin
A decline in gross margin due to higher costs could pressure profitability, requiring efficiency improvements to maintain long-term financial health.
Increased Operating Loss
Rising operating losses highlight challenges in cost management, which could hinder profitability and require strategic adjustments to improve financial performance.
High Cash Burn
High cash burn indicates potential liquidity issues, necessitating improved cash flow management to ensure sustainable operations and future growth.
Myomo (MYO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$37.67M
Dividend YieldN/A
Average Volume (3M)698.42K
Price to Earnings (P/E)―
Beta (1Y)1.38
Revenue Growth64.99%
EPS Growth-25.54%
CountryUS
Employees184
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.09
Shares Outstanding38,435,524
10 Day Avg. Volume628,546
30 Day Avg. Volume698,416
Financial Highlights & Ratios
PEG Ratio0.92
Price to Book (P/B)9.84
Price to Sales (P/S)7.47
P/FCF Ratio-52.30
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue0.90
Enterprise Value/Gross Profit1.35
Enterprise Value/Ebitda-3.70
Forecast
1Y Price Target
$5.75Price Target Upside525.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Myomo Business Overview & Revenue Model
Company DescriptionMyomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
How the Company Makes MoneyMyomo generates revenue primarily through the sale of its MyoPro orthotic devices, which are sold directly to healthcare providers and through various distribution channels. The company also benefits from reimbursement programs that allow patients to have their MyoPro devices covered by insurance, which significantly enhances market access and sales potential. Additionally, Myomo collaborates with healthcare institutions and rehabilitation centers to provide customized solutions and services, further expanding its reach and revenue potential. Strategic partnerships with medical professionals, rehabilitation facilities, and insurance providers play a crucial role in driving sales and increasing the adoption of its products.
Myomo Earnings Call Summary
Earnings Call Date:Nov 10, 2025
(Q3-2025)
| Next Earnings Date:Mar 16, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mixed picture with notable revenue growth and strategic expansions, particularly in international markets and the O&P channel. However, challenges such as decreased gross margin, increased operating loss, and high cash burn were significant concerns. The company's reaffirmation of financial guidance and steps to optimize costs and advertising were positive, but the issues with Medicare Advantage revenue and increased losses present challenges.Q3-2025 Updates
Positive Updates
Revenue Growth and International Success
Myomo reported a revenue of $10.1 million for Q3 2025, marking a 10% increase compared to the prior year, driven by record revenues in international markets, especially Germany.
Increased Authorizations and Orders
For the first time this year, Myomo saw a sequential increase in quarterly authorizations and orders, supported by more Medicare Advantage payer authorizations.
Expanding O&P Channel
Revenue from the O&P channel increased by 154% year over year, reaching $900,000. The international revenue, particularly from Germany, was a record $1.8 million, up 63%.
Cost Reduction and Operating Leverage
Steps were taken to reduce operating costs and improve gross margin, along with plans to optimize advertising spend and expand the MyoConnect program.
Financial Guidance Reaffirmed
Myomo reiterated its full 2025 annual guidance of $40 million to $42 million in revenue, representing an increase of more than 23% over the previous year.
Negative Updates
Decline in Medicare Advantage Revenue
Medicare Advantage revenue was down 18% compared to the prior year, constrained by high pre-authorization denial rates, resulting in a time-consuming appeals process.
Decreased Gross Margin
Gross margin for Q3 2025 was 63.8%, down from 75.4% in the prior year, impacted by higher payroll and lease expenses, material costs, and unfavorable overhead absorption.
Increased Operating Loss
The operating loss for Q3 2025 was $3.5 million, compared to $1 million in the prior year. The net loss increased to $3.7 million from $1 million in the prior year.
High Cash Burn
Cash burn was $2.9 million in Q3 2025, driven by operating activities and capital expenditures related to manufacturing space expansion and product development.
Company Guidance
During the Myomo Third Quarter 2025 Financial Results Conference Call, CEO Paul Gudonis provided guidance that the company anticipates achieving full-year 2025 revenue within the range of $40 million to $42 million, reflecting an over 23% increase compared to the previous year. This optimistic outlook is supported by a robust performance in the third quarter, where the company reported revenues of $10.1 million, driven by a 16% increase in MyoPro revenue units and strong international sales, notably a 63% rise in Germany. Additionally, the company is expanding its MyoConnect program and O&P channel to lower customer acquisition costs while also seeing a positive trend in Medicare Advantage authorizations. Myomo's strategic initiatives include expanding insurance coverage, reducing operating costs, and enhancing patient identification processes. CFO Dave Henry highlighted a gross margin of 63.8% and operating expenses totaling $10 million, with a focus on improving operating leverage and lowering cash burn in 2026. The company reiterated its commitment to scaling its business towards sustainable profitability and positive cash flow.Myomo Financial Statement Overview
Summary
Myomo is experiencing revenue growth, but profitability and cash flow challenges persist. The company has increased its leverage, which could pose risks if not managed carefully. Improving operational efficiency and cash flow generation are critical for enhancing financial stability and long-term success.Income Statement
The company has shown consistent revenue growth, with a TTM revenue growth rate of 2.17%. However, profitability remains a challenge, as indicated by negative net profit and EBIT margins. The gross profit margin is relatively strong at 69.24%, but the company needs to address its operational inefficiencies to improve overall profitability.Balance Sheet
The debt-to-equity ratio has increased to 0.71 in the TTM period, indicating a rise in leverage. Return on equity is negative, reflecting ongoing losses. The equity ratio is not explicitly provided, but the balance sheet shows a moderate level of equity relative to total assets. The company needs to manage its debt levels and improve its equity position.Cash Flow
Cash flow remains a significant concern, with negative operating and free cash flows. The free cash flow to net income ratio is above 1, indicating that cash flow is less negative than net income, but the overall cash flow position is weak. The company must focus on improving cash generation to support operations and growth.| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 41.64M | 32.55M | 19.24M | 15.56M | 13.86M | 7.58M |
| Gross Profit | 27.72M | 23.19M | 13.18M | 10.25M | 10.31M | 4.98M |
| EBITDA | -10.10M | -5.04M | -7.71M | -10.13M | -9.93M | -10.98M |
| Net Income | -12.02M | -6.18M | -8.15M | -10.72M | -10.37M | -11.56M |
Balance Sheet | ||||||
| Total Assets | 34.08M | 42.24M | 14.58M | 10.16M | 20.10M | 14.71M |
| Cash, Cash Equivalents and Short-Term Investments | 12.55M | 24.87M | 8.87M | 5.35M | 15.52M | 12.24M |
| Total Debt | 12.30M | 8.11M | 601.30K | 553.91K | 735.00K | 173.44K |
| Total Liabilities | 19.45M | 17.53M | 5.59M | 3.80M | 4.69M | 3.14M |
| Stockholders Equity | 14.63M | 24.71M | 8.99M | 6.36M | 15.41M | 11.57M |
Cash Flow | ||||||
| Free Cash Flow | -13.85M | -4.65M | -6.32M | -10.35M | -9.87M | -9.08M |
| Operating Cash Flow | -10.01M | -3.29M | -6.17M | -10.23M | -9.55M | -9.03M |
| Investing Cash Flow | -3.82M | 259.98K | -2.03M | -310.79K | -326.46K | -45.75K |
| Financing Cash Flow | 19.68M | 20.93M | 9.71M | 376.86K | 13.17M | 16.78M |
Myomo Technical Analysis
Negative
0.92
Price Trends
0.92
Positive
0.97
Positive
2.05
Negative
Market Momentum
0.02
Negative
50.51
Neutral
56.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYO, the sentiment is Negative. The current price of 0.92 is below the 20-day moving average (MA) of 0.99, below the 50-day MA of 0.92, and below the 200-day MA of 2.05, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 50.51 is Neutral, neither overbought nor oversold. The STOCH value of 56.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MYO.
Myomo Risk Analysis
Myomo disclosed 50 risk factors in its most recent earnings report. Myomo reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Myomo Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $40.22M | -2.80 | -337.84% | ― | 27.90% | 1.62% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $37.67M | -3.40 | -100.51% | ― | 64.99% | -25.54% | |
46 Neutral | $20.20M | -0.18 | -210.36% | ― | -70.54% | 70.03% | |
45 Neutral | $18.29M | -0.28 | -148.93% | ― | ― | 15.03% | |
42 Neutral | $33.57M | -2.04 | ― | ― | ― | ― |
* Healthcare Sector Average
MYO
Myomo
0.98
-5.02
-83.67%
ECOR
Electrocore
5.03
-10.41
-67.42%
MODD
Modular Medical
0.48
-0.78
-61.90%
RBOT
Vicarious Surgical
2.57
-10.82
-80.81%
ADGM
Adagio Medical Holdings
0.95
0.06
7.08%
IINN
Inspira Technologies Oxy BHN
0.94
-0.12
-11.32%
Myomo Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Myomo Secures $17.5 Million Loan for Growth
Positive
Nov 10, 2025
On November 4, 2025, Myomo, Inc. entered into a Loan and Security Agreement with Avenue Capital Management II, L.P. and Avenue Venture Opportunities Fund II, L.P., securing up to $17.5 million in term loans. This financial arrangement aims to support Myomo’s operational needs, including repaying existing borrowings and general corporate purposes. The company reported a strong third quarter in 2025, with revenues reaching $10.1 million, a 10% increase from the previous year, driven by record levels in both U.S. and international O&P revenues. Despite a decrease in gross margin due to higher costs, Myomo is focusing on cost reduction projects and strategic marketing initiatives like MyoConnect to enhance its patient pipeline and reduce costs.
The most recent analyst rating on (MYO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Myomo stock, see the MYO Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.